Floatz logo

Evomela

Large B-cell Lymphoma

Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

72 Active assets in the Large B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Axicabtagene Ciloleucel
Zhejiang Cancer Hospital
Phase 4BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Fludarabine
M.D. Anderson Cancer Center
Phase 4BB
ETOPOSIDE
University of California, Davis
Phase 2/3BB
Inno-206
Ruijin Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Evomela is also rated in:

diffuse large B-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
myeloproliferative neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →